Today, AtheroNova announced that Erik SG Stroes, MD, Chair and Professor at the Department of Vascular Medicine at the Academic Medical Center (AMC), Amsterdam has joined the Company as a member of its Clinical Advisory Board.
Professor Stroes is well-known for his cutting edge clinical care of cardiovascular patients and for his revolutionary clinical research activities that have contributed to a very substantial reduction in the consequences of cardiovascular disease over the past decade. This is an important addition to the company as AtheroNova enhances its scientific and medical teams in its move into a clinical stage company.
Dr. Stroes has been involved in the development of novel therapeutic moieties for dyslipidemia, such as Lipoprotein lipase gene therapy, apoB antisense, reconstituted HDL-infusion, and other novel compounds. He has also focused on the role of the vessel wall in atherogenesis development. During the 1990s, he studied modulation of endothelial nitric oxide synthase (co-factor suppletion, gene therapy) as a major topic for research, leading to the first demonstration of the relevance of nitric oxide synthase uncoupling in humans with dyslipidemia. Since his transition to the AMC, Dr. Stroes has focused on lipid disorders in relation to atherogenesis, and has participated in numerous lipid lowering trials using surrogate markers such as intima media thickness (ENHANCE study) and flow mediated dilation. More lately, he has observed that 3T-MRI has been added as surrogate marker for vascular disease progression. In addition, his observations on novel gene defects contributing to lipid disorders (HDLc, hypertriglyceridemia) have been pursued by collecting autosomal dominant families with these disorders. Dr. Stroes has published more than 195 papers in peer reviewed journals.